Metastatic non-small cell lung cancer in Brazil: Treatment heterogeneity in routine clinical practice

Clinics

Volumn 62, Issue 4, 2007, Pages 397-404

  Naime, Fauzia F ^a   Younes, Riad Naim ^b   Kersten, Bruno G ^c   Anelli, Agnaldo ^d   Beato, Carlos Augusto M ^c   Andrade, Rogério M ^a   Carrara, Marcella P ^a   Gross, Jefferson Luiz ^b  

^a Instituto Paulista de Cancerologia   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c Hospital Amaral Carvalho de Jau   (Brazil)

^d NONE   (Brazil)

Author keywords

Chemotherapy; Lung Cancer; Metastases; Non Small Cell Lung Cancer (NSCLC); Routine clinical practice

Indexed keywords

EID: 34548791638     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322007000400005     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30.
2. Intituto Nacional do Cancer. Estimativas 2006. Incidência de cancer no Brasil. Avaiable at:www.inca.gov.br/estimativa/2006/index.asp?link= conteudoview.asp&ID=5. AcessedNovember7,2006.
3. National Cancer Institute. Non-small cell lung cancer (PDQ®: treatment. Avaiable at: www.cancer.gov/cancertopics/pdq/treatment/non-small- celllung/healthprofessional. AcessedNovember7, 2006.
4. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced nonsmall-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol. 2004;15(12):1782-9.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med. 2002;346(2):92-8.
6. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3261-8.
7. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
8. Kaplan ZL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
9. Bunn PA, Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4:1087-100.
10. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy vs single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602-13.
11. Weick JK, Crowley J, Natale RB, et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-smallcell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991; 9:1157-62.
12. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311(7010):899-909.
13. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Non-small Cell Lung Cancer. Available at: www.nccn.org/professional/physicians/ nsclc.pdf. Acessed November 8, 2006.
14. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al.Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;9(13):3210-8.
15. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin J Clin Oncol. 2001;19(5):1336-43.
16. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV nonsmall-cell lung cancer. J Clin Oncol. 2002;20(5):1335-43.
17. von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-smallcell lung cancer. Br J Cancer. 2006;95(8):966-73.
18. Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC. Who gets chemotherapy for metastatic lung cancer? Chest. 2000;117(5):1239-46.
19. Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003;21(17):3207-13.
20. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin J Clin Oncol. 2001;19(5):1336-43.
21. Stinchcombe TE, Lee CB, Socinski MA. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer. 2006; 7 Suppl 4:S111-7.